TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

M. Jasek, L. P. Gondek, N. Bejanyan, R. Tiu, J. Huh, K. S. Theil, C. O'Keefe, M. A. McDevitt, J. P. MacIejewski

Research output: Contribution to journalLetterpeer-review

68 Scopus citations
Original languageEnglish
Pages (from-to)216-219
Number of pages4
Issue number1
StatePublished - Jan 2010

Bibliographical note

Funding Information:
This work was supported in part by RO1HL-082983, U54 RR019391 K24 HL-077522 and by Grant from AA&MDS International Foundation and Robert Duggan Charitable Fund (JPM).

Cite this